Size | Price | Stock | Qty |
---|---|---|---|
100mg |
|
||
500mg |
|
||
Other Sizes |
|
ln Vitro |
COX-2 is inhibited by the antioxidant gallic acid[1]. Following an 18-hour gallic acid treatment, 26.4% of the neutrophils that required treatment—or 40.3% of the total—were still alive after treatment. Cumene cannot be broken down by gallic acid and myocyte lysis cannot occur [3].
|
---|---|
ln Vivo |
The gallic acid group's body weight (2.5±0.69 g, p=0.76) and food approval amount (2.6±0.08 g/day, p=0.69) differed substantially from the body weight (food approval amount: 2.41±0.14 g/day and body weight: 2.83±0.84 g/day). After two weeks of treatment, there was a considerable improvement in the gallic acid group's blood pressure tolerance. After two weeks of therapy, the gallic acid group's blood pressure tolerance was also significantly lowered, with tachycardia observed at 90 and 120 minutes (p<0.05). The group's serum triglyceride concentration was significantly lower in the gallic acid group (0.67±0.03 mM, p<0.05) than in the Manhattan group (1.08±0.20 mM). Gallic acid (3.01±0.18 mM) and Manhattan (3.19±0.27 mM). the overall depth enrichment of the group [2].
|
References |
[1]. Amaravani M, et al. COX-2 structural analysis and docking studies with gallic acid structural analogues. Springerplus. 2012 Dec;1(1):58.
[2]. Bak EJ, et al. Gallic acid improves glucose tolerance and triglyceride concentration in diet-induced obesity mice. Scand J Clin Lab Invest. 2013 Dec;73(8):607-14. [3]. Cheng Y, et al. Plant Natural Products Calycosin and Gallic Acid Synergistically Attenuate Neutrophil Infiltration and Subsequent Injury in Isoproterenol-Induced Myocardial Infarction: A Possible Role for Leukotriene B4 12-Hydroxydehydrogenase? Oxid Med Cell Longev. 2015;2015:434052 |
Molecular Formula |
C7H6O5
|
---|---|
Molecular Weight |
170.12
|
Exact Mass |
170.0215
|
CAS # |
149-91-7
|
Related CAS # |
Gallic acid hydrate;5995-86-8;Gallic acid-d2;294660-92-7
|
Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
SMILES |
O([H])C1C(=C([H])C(C(=O)O[H])=C([H])C=1O[H])O[H]
|
Synonyms |
HSDB2117; HSDB 2117; Gallic acid
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : ≥ 100 mg/mL (~587.82 mM)
H2O : ~8.33 mg/mL (~48.97 mM) |
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (14.70 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (14.70 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 5.8782 mL | 29.3910 mL | 58.7820 mL | |
5 mM | 1.1756 mL | 5.8782 mL | 11.7564 mL | |
10 mM | 0.5878 mL | 2.9391 mL | 5.8782 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.